Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of X842 capsule-containing bismuth quadruple therapy for Helicobacter pylori eradication
CTR20260168Phase 3Active
- Sponsor
- Sino-Nordic Pharmaceutical
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of linaprazan glurate in Helicobacter pylori infection, sponsored by Sino-Nordic Pharmaceutical. Started Mar 2026; status: active.
02
Drugs
linaprazan glurate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on CTR20260168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260168.